Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 799-808

  Monk, Bradley J ^a   Poveda, Andrés ^b   Vergote, Ignace ^c   Raspagliesi, Francesco ^d   Fujiwara, Keiichi ^e   Bae, Duk Soo ^f   Oaknin, Ana ^g   Ray Coquard, Isabelle ^h   Provencher, Diane M ⁱ   Karlan, Beth Y ^j   Lhommé, Catherine ^k   Richardson, Gary ^l   Rincón, Dolores Gallardo ^m   Coleman, Robert L ⁿ   Herzog, Thomas J ^o   Marth, Christian ^p   Brize, Arija ^q   Fabbro, Michel ^r   Redondo, Andrés ^s   Bamias, Aristotelis ^t   Tassoudji, Marjan ^u   Navale, Lynn ^v   Warner, Douglas J ^v   Oza, Amit M ^w   more..

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f Samsung Medical Center   (South Korea)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h UNIVERSITÉ LYON 1   (France)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l CABRINI HOSPITAL   (Australia)

^m INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o NewYork Presbyterian Hospital   (United States)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^r CENTRE VAL D AURELLE   (France)

^s HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^t UNIVERSITY OF ATHENS   (Greece)

^u AMGEN LTD   (United Kingdom)

^v AMGEN INC   (United States)

^w PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLACEBO; TREBANANIB;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; AUSTRALIA; BACKACHE; BLEEDING; BLURRED VISION; BODY WEIGHT DISORDER; CANCER GRADING; CANCER INCIDENCE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; EDEMA; EQ 5D; FATIGUE; FEMALE; FEVER; GENERALIZED EDEMA; HEADACHE; HEALTH STATUS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LACRIMATION DISORDER; LIMB PAIN; LUNG EMBOLISM; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NORTH AMERICA; OVARY CARCINOMA; OVERALL SURVIVAL; PARESTHESIA; PARONYCHIA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SKIN FISSURE; THROMBOSIS; UPPER ABDOMINAL PAIN; UTERINE TUBE TUMOR; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE; WESTERN EUROPE; WOUND HEALING IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RECOMBINANT FUSION PROTEINS; WITHHOLDING TREATMENT;

EID: 84903517779     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70244-X     Document Type: Article

References (33)

1. Global health observatory data repository. Number of deaths: world by cause WHO, (accessed May 21, 2014). http://apps.who.int/gho/data/node.main.CODWORLD?lang=en.
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013, 10:211-224.
3. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
4. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
5. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
6. Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?. J Clin Oncol 2007, 25:5150-5152.
7. Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer [abstract]. Int J Gyn Cancer 2013, 23:PL01.
8. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
9. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
10. Du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16) [abstract]. Proc Am Soc J Clin Oncol 2013, 31. LBA5503.
11. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014, 32:1309-1316.
12. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
13. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer 2013, 49. LBA10.
14. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9:2641-2651.
15. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27:3557-3565.
16. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012, 30:362-371.
17. Monk BJ, Minion L, Lambrechts S, Vergote IB, Devoogdt N, Karlan BY Incidence and management of edema associated with trebananib (AMG 386). Gynecol Oncol 2013, 130:636-641.
18. Baird RD, Tan DS, Kaye SB Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010, 7:575-582.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
20. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001, 19:1809-1817.
21. Common terminology criteria for adverse events v3.0 (CTCAE) Cancer Therapy Evaluation Program, (accessed May 21, 2014). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
22. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011, 21:419-423.
23. Collett D Modelling survival data in medical research 2003, Chapman and Hall/CRC Press LLC, Boca Raton, FL. 2nd edn.
24. Lin DY, Wei LJ, Ying Z Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993, 80:557-572.
25. Herzog TJ, Armstrong DK, Brady MF, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014, 132:8-17.
26. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-4707.
27. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107-3114.
28. Broglio KR, Berry DA Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
29. Eskens FA, Verweij J The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42:3127-3139.
30. Colombo N Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. Future Oncol 2013, 9:19-23.
31. Peeters M, Strickland AH, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013, 108:503-511.
32. Eatock MM, Szanto J, Tebbutt NC, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine (CX) in patients (pts) with metastatic gastroesophageal adenocarcinoma. Proc Am Soc Clin Oncol 2011, 29. abstract 66.
33. Armstrong DK Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7(suppl 5):20-28.